Bioventus Inc.
BVS
$6.56
$0.010.15%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 564.14M | 567.70M | 573.28M | 555.06M | 536.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 564.14M | 567.70M | 573.28M | 555.06M | 536.89M |
| Cost of Revenue | 182.79M | 184.80M | 185.05M | 183.19M | 179.72M |
| Gross Profit | 381.35M | 382.90M | 388.23M | 371.87M | 357.17M |
| SG&A Expenses | 320.15M | 325.22M | 330.51M | 322.34M | 311.12M |
| Depreciation & Amortization | 6.87M | 7.49M | 7.65M | 7.99M | 8.24M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 523.04M | 531.78M | 537.11M | 527.42M | 512.19M |
| Operating Income | 41.10M | 35.92M | 36.17M | 27.64M | 24.70M |
| Income Before Tax | 2.30M | -49.57M | -51.63M | -60.27M | -63.63M |
| Income Tax Expenses | 2.09M | -6.30M | -5.29M | -6.59M | -6.58M |
| Earnings from Continuing Operations | 0.21 | -43.28 | -46.34 | -53.68 | -57.05 |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -369.00K | 9.98M | 10.79M | 12.18M | 13.07M |
| Net Income | -158.00K | -33.30M | -35.55M | -41.49M | -43.97M |
| EBIT | 41.10M | 35.92M | 36.17M | 27.64M | 24.70M |
| EBITDA | 82.08M | 77.94M | 78.11M | 71.50M | 70.11M |
| EPS Basic | 0.00 | -0.52 | -0.55 | -0.65 | -0.69 |
| Normalized Basic EPS | 0.07 | 0.16 | 0.16 | 0.08 | 0.05 |
| EPS Diluted | -0.01 | -0.52 | -0.55 | -0.65 | -0.69 |
| Normalized Diluted EPS | 0.07 | 0.16 | 0.16 | 0.08 | 0.05 |
| Average Basic Shares Outstanding | 263.22M | 260.78M | 258.15M | 255.80M | 253.36M |
| Average Diluted Shares Outstanding | 265.26M | 260.78M | 258.15M | 255.80M | 253.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |